zantac lawsuit

Zantac MDL Moves Forward As Parties Select Cases for Bellwether Trials

On April 1, 2020, the Food and Drug Administration (FDA) requested manufacturers withdraw all prescription and over-the-counter ranitidine (Zantac) drugs from the market. This, after tests, showed the products could contain N-nitrosodimethylamine (NDMA), a potent carcinogen.

Meanwhile, many consumers had already filed Zantac lawsuits, claiming that they had taken the drug for years and were later diagnosed with cancer as a result. In February 2020, the U.S. Judicial Panel on Multidistrict Litigation (JPML) consolidated all federally filed Zantac lawsuits in the U.S. District Court for the Southern District of Florida for consolidated pre-trial proceedings.

Now the judge overseeing the Zantac MDL has ordered the parties to randomly select 200 cases to be part of an initial discovery pool.

Categories MDL

* Word-Use Disclaimer

Legal funding is not a loan. It is the non-recourse purchase of an equitable lien in a plaintiffs’ legal claim. Words such as ‘loans,’ ‘lending,’ ‘borrow,’ etc., are used for search and marketing purposes only.
More info

TriMark Legal Funding LLC
1056 Green Acres Rd #102
Eugene, OR 97408